EUVIMEDObjevte EUVIMED
Crossref

RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma‐like mesenchymal tumors

Marialetizia Motta, Sabina Barresi, Simone Pizzi, Delfina Bifano, Jennifer Lopez Marti, Marta Garrido-Pontnou, Elisabetta Flex, Alessandro Bruselles, Isabella Giovannoni, Giovannina Rotundo, Alessandra Fragale, Valentina Tirelli and 5 more

The Journal of Pathology · 2024

DOI: 10.1002/path.6272 ↗

At a glance

Journal article in The Journal of Pathology, 2024. Written by Marialetizia Motta and 16 co-authors. Institution: Molecular Genetics and Functional Genomics Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Major MEDLINE topics: Fibrosarcoma, Proto-Oncogene Proteins c-raf, Oncogene Proteins, Fusion, Nephroma, Mesoblastic. Cited 9 times so far (Crossref); 45 references. Funded by: Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Infantile fibrosarcomas (IFS) and congenital mesoblastic nephroma (CMN) are rare myofibroblastic tumors of infancy and early childhood commonly harboring the ETV6 :: NTRK3 gene fusion. IFS/CMN are considered as tumors with an ‘intermediate prognosis’ as they are locally aggressive, but rarely metastasize, and generally have a favorable outcome. A fraction of IFS/CMN‐related neoplasms are negative for the ETV6 :: NTRK3 gene rearrangement and are characterized by other chimeric proteins promoting MAPK signaling upregulation. In a large proportion of these tumors, which are classified as IFS‐like mesenchymal neoplasms, the contributing molecular events remain to be identified. Here, we report three distinct rearrangements involving RAF1 among eight ETV6 :: NTRK3 gene fusion‐negative tumors with an original histological diagnosis of IFS/CMN. The three fusion proteins retain the entire catalytic domain of the kinase. Two chimeric products, GOLGA4::RAF1 and LRRFIP2::RAF1, had previously been reported as driver events in different cancers, whereas the third, CLIP1::RAF1, represents a novel fusion protein. We demonstrate that CLIP1::RAF1 acts as a bona fide oncoprotein promoting cell proliferation and migration through constitutive upregulation of MAPK signaling. We show that the CLIP1::RAF1 hyperactive behavior does not require RAS activation and is mediated by constitutive 14‐3‐3 protein‐independent dimerization of the chimeric protein. As previously reported for the ETV6::NTRK3 fusion protein, CLIP1::RAF1 similarly upregulates PI3K‐AKT signaling. Our findings document that RAF1 gene rearrangements represent a recurrent event in ETV6 :: NTRK3 ‐negative IFS/CMN and provide a rationale for the use of inhibitors directed to suppress MAPK and PI3K‐AKT signaling in these cancers. © 2024 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

FibrosarcomaProto-Oncogene Proteins c-rafOncogene Proteins, FusionNephroma, MesoblasticHumansInfantFemaleMaleKidney NeoplasmsGene FusionSignal TransductionProto-Oncogene Proteins c-etsCell ProliferationGene RearrangementETS Translocation Variant 6 ProteinReceptor, trkC

Author keywords

MAPK signalingPI3K‐AKT signalingRAF kinasefusion proteinsinfantile fibrosarcoma

Substances

Raf1 protein, humanProto-Oncogene Proteins c-rafOncogene Proteins, FusionProto-Oncogene Proteins c-etsETV6-NTRK3 fusion protein, humanETS Translocation Variant 6 ProteinReceptor, trkC

Authors and institutions

  • Molecular Genetics and Functional Genomics Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Pathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Pathology Unit, Santobono-Pausilipon Children's Hospital, Naples, Italy.
  • Department of Pathology, Hospital Nacional de Pediatria Juan P. Garrahan, Buenos Aires, Argentina.
  • Department of Pathology, Vall d'Hebron Hospital Universitari, Barcelona, Spain.
  • Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

ORCID profiles: Rita Alaggio, Marco Tartaglia

Funding

  • Associazione Italiana per la Ricerca sul Cancro
  • Ministero della Salute

Cite

APA

Motta, M., Barresi, S., Pizzi, S., Bifano, D., Lopez Marti, J., Garrido-Pontnou, M., Flex, E., Bruselles, A., Giovannoni, I., Rotundo, G., Fragale, A., Tirelli, V., Vallese, S., Ciolfi, A., Bisogno, G., Alaggio, R., & Tartaglia, M. (2024). RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma‐like mesenchymal tumors. The Journal of Pathology. https://doi.org/10.1002/path.6272

Vancouver

Motta M, Barresi S, Pizzi S, Bifano D, Lopez Marti J, Garrido-Pontnou M, et al. RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma‐like mesenchymal tumors. The Journal of Pathology. 2024. doi:10.1002/path.6272

BibTeX
@article{Motta2024,
  author = {Motta, Marialetizia and Barresi, Sabina and Pizzi, Simone and Bifano, Delfina and Lopez Marti, Jennifer and Garrido-Pontnou, Marta and Flex, Elisabetta and Bruselles, Alessandro and Giovannoni, Isabella and Rotundo, Giovannina and Fragale, Alessandra and Tirelli, Valentina and Vallese, Silvia and Ciolfi, Andrea and Bisogno, Gianni and Alaggio, Rita and Tartaglia, Marco},
  title = {RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma‐like mesenchymal tumors},
  journal = {The Journal of Pathology},
  year = {2024},
  doi = {10.1002/path.6272}
}
Start for free →